Barclays PLC Has $2.83 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Barclays PLC cut its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 35.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 331,242 shares of the biopharmaceutical company's stock after selling 180,280 shares during the quarter. Barclays PLC owned 0.21% of Ocular Therapeutix worth $2,830,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Courier Capital LLC acquired a new position in Ocular Therapeutix during the fourth quarter worth approximately $482,000. RoundAngle Advisors LLC acquired a new position in shares of Ocular Therapeutix in the fourth quarter valued at approximately $1,695,000. SG Americas Securities LLC grew its holdings in Ocular Therapeutix by 58.7% in the 4th quarter. SG Americas Securities LLC now owns 71,698 shares of the biopharmaceutical company's stock valued at $612,000 after buying an additional 26,511 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Ocular Therapeutix by 11.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company's stock worth $285,000 after buying an additional 3,347 shares during the period. Finally, Deltec Asset Management LLC lifted its holdings in shares of Ocular Therapeutix by 0.6% during the 4th quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company's stock valued at $22,344,000 after acquiring an additional 16,300 shares in the last quarter. Hedge funds and other institutional investors own 59.21% of the company's stock.

Wall Street Analysts Forecast Growth

OCUL has been the subject of a number of recent analyst reports. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Needham & Company LLC restated a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday, April 8th. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price objective for the company. Finally, William Blair started coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They set an "outperform" rating for the company. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $16.38.

Ocular Therapeutix Trading Up 3.2 %

Shares of OCUL stock traded up $0.27 on Friday, reaching $8.80. 1,558,376 shares of the stock were exchanged, compared to its average volume of 1,449,511. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a one year low of $4.79 and a one year high of $11.78. The stock has a market cap of $1.40 billion, a PE ratio of -6.67 and a beta of 1.51. The stock has a 50 day moving average price of $7.40 and a 200 day moving average price of $8.43.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The company had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Equities research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Donald Notman sold 11,119 shares of the company's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the transaction, the insider now owns 193,444 shares in the company, valued at approximately $1,510,797.64. This represents a 5.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the sale, the insider now directly owns 3,520,318 shares of the company's stock, valued at approximately $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.50% of the stock is owned by corporate insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.